These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 3624207)

  • 1. Predicting outcome of neuroleptic treatment on the basis of subjective response and early clinical improvement.
    Bartkó G; Herczeg I; Békésy M
    J Clin Psychiatry; 1987 Sep; 48(9):363-5. PubMed ID: 3624207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haloperidol plasma level after a test dose as predictor for the clinical response to treatment in acute schizophrenic patients.
    Louza Neto MR; Müller-Spahn F; Rüther E; Scherer J
    Pharmacopsychiatry; 1988 Sep; 21(5):226-31. PubMed ID: 3227054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum prolactin as a correlate of clinical response to haloperidol.
    Van Putten T; Marder SR; Mintz J
    J Clin Psychopharmacol; 1991 Dec; 11(6):357-61. PubMed ID: 1770154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of therapeutic response to haloperidol in acute schizophrenia.
    McEvoy JP; Schooler NR; Wilson WH
    Psychopharmacol Bull; 1991; 27(2):97-101. PubMed ID: 1924667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haloperidol: therapeutic window in schizophrenia.
    Palao DJ; Arauxo A; Brunet M; Bernardo M; Haro JM; Ferrer J; Gonzalez-Monclus E
    J Clin Psychopharmacol; 1994 Oct; 14(5):303-10. PubMed ID: 7806684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma catecholamine metabolites and early response to haloperidol.
    Bowers MB; Swigar ME; Jatlow PI; Goicoechea N
    J Clin Psychiatry; 1984 Jun; 45(6):248-51. PubMed ID: 6725216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haloperidol decanoate in schizophreniform disorders. Clinical and neuroendocrine aspects.
    Meco G; Casacchia M; Attenni M; Iafrate A; Castellana F; Ecari U
    Acta Psychiatr Belg; 1983; 83(1):57-68. PubMed ID: 6613612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial improvement as a criterion for drug choice in acute schizophrenia.
    Klimke A; Klieser E; Lehmann E; Miele L
    Pharmacopsychiatry; 1993 Jan; 26(1):25-9. PubMed ID: 8104348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The assessment and clinical implications of haloperidol acute-dose, steady-state, and withdrawal pharmacokinetics.
    Khot V; DeVane CL; Korpi ER; Venable D; Bigelow LB; Wyatt RJ; Kirch DG
    J Clin Psychopharmacol; 1993 Apr; 13(2):120-7. PubMed ID: 8463444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Value of neuroleptic therapy in the self assessment of schizophrenic patients].
    Heim M
    Psychiatr Neurol Med Psychol (Leipz); 1987 Aug; 39(8):487-91. PubMed ID: 3685210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Length of psychiatric hospitalization and prediction of antipsychotic response.
    Zemlan FP; Thienhaus OJ; Garver DL
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(1):13-24. PubMed ID: 2300678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic protocol for predicting plasma haloperidol concentrations.
    Miller DD; Perry PJ; Kelly MW; Coryell WH; Arndt SV
    J Clin Psychopharmacol; 1990 Jun; 10(3):207-12. PubMed ID: 2376619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of haloperidol in high doses in schizophrenia. Clinical, biochemical and pharmacokinetic study].
    Scatton B; Zarifian E; Bianchetti G; Cuche H; Loo H; Morselli PL
    Encephale; 1982; 8(1):1-8. PubMed ID: 7094868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial improvement as predictor of outcome of neuroleptic treatment.
    Nedopil N; Rüther E
    Pharmacopsychiatria; 1981 Nov; 14(6):205-7. PubMed ID: 6119712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine D2 receptor gene polymorphisms predict well the response to dopamine antagonists at therapeutic dosages in patients with schizophrenia.
    Sakumoto N; Kondo T; Mihara K; Suzuki A; Yasui-Furukori N
    Psychiatry Clin Neurosci; 2007 Apr; 61(2):174-80. PubMed ID: 17362435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance.
    Singh MM
    Dis Nerv Syst; 1976 Apr; 37(4):191-6. PubMed ID: 767080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognosis of short-term outcome in the first admission for psychosis].
    Verdoux H; Liraud F; Gonzales B; Fournet O; Pauillac P; Assens F; Abalan F; Beaussier JP; Gaussares C; Etchegaray B; Bourgeois M
    Encephale; 1999; 25(3):213-20. PubMed ID: 10434146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to antipsychotic medication: the doctor's and the consumer's view.
    Van Putten T; May PR; Marder SR
    Am J Psychiatry; 1984 Jan; 141(1):16-9. PubMed ID: 6691455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.